NCT05101135View on ClinicalTrials.gov

To Evaluate the Efficacy and Safety of JT-001 add-on in Paatients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin and Dapagliflozin

PHASE3UnknownINTERVENTIONAL
Enrollment

256

Participants

Timeline

Start Date

November 17, 2021

Primary Completion Date

October 31, 2022

Study Completion Date

October 31, 2022

Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG

JT-001

Subjects take the investigational products once a day for 24 weeks.

DRUG

JT-001 Placebo

Subjects take the investigational products once a day for 24 weeks.

Trial Locations (1)

Unknown

RECRUITING

Severance Hospital, Seoul

Sponsors
All Listed Sponsors
lead

Jeil Pharmaceutical Co., Ltd.

INDUSTRY